{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:43:23Z","timestamp":1795034603939,"version":"4.10.2"},"reference-count":55,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Hydroxyurea provides effective disease-modifying treatment for people with sickle cell anemia (SCA), especially when escalated to maximum tolerated dose (MTD), which has wide interpatient dosing variability due to pharmacokinetic (PK) differences. Whether hydroxyurea PK parameters differ among children with SCA in different global regions is unknown. We compared hydroxyurea PK parameters among children with SCA from 5 clinical trials: HUSTLE (United States), TREAT (United States), NOHARM (Uganda), REACH (Uganda and Kenya), and EXTEND (Jamaica). Key hydroxyurea PK parameters were determined using HdxSim, a validated hydroxyurea PK software program. The results were compared across regions by analysis of variance. PK profiles from 451 children with SCA (146 from the United States, 265 from Africa, and 40 from the Caribbean) were included. Children from Africa had slightly lower volumes of distribution, but absorption rate and clearance were similar across regions. The PK-recommended doses to achieve MTD were statistically different but clinically similar across the United States (26.6 \u00b1 5.9 mg\/kg per day), Africa (27.6 \u00b1 6.5 mg\/kg per day), and the Caribbean (25.2 \u00b1 4.7 mg\/kg per day) (P = .04). In multivariable regression, younger age and increased reticulocyte counts were associated with higher PK-recommended doses. Hydroxyurea PK parameters in children with SCA differ minimally across global populations, predicting clinically similar doses to achieve MTD. Individualized hydroxyurea dosing based on a PK-population model derived from US children with SCA can be used broadly to maximize the benefits of this critical medication in other global populations. These trials were registered at www.ClinicalTrials.gov as #NCT00305175 (HUSTLE), #NCT02286154 (TREAT), #NCT01976416 (NOHARM), #NCT01966731 (REACH), and #NCT02556099 (EXTEND).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017254","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:58:12Z","timestamp":1759262292000},"page":"418-427","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populations"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5823-0218","authenticated-orcid":false,"given":"Alexandra","family":"Power-Hays","sequence":"first","affiliation":[{"name":"1Division of Hematology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"},{"name":"2Department of Pediatrics, Global Health Center, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"},{"name":"3Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-3187","authenticated-orcid":false,"given":"Kathryn E.","family":"McElhinney","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4456-2382","authenticated-orcid":false,"given":"Thomas N.","family":"Williams","sequence":"additional","affiliation":[{"name":"4Department of Epidemiology and Demography, Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya"},{"name":"5Department of Medicine, Institute of Global Health Innovation, Imperial College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8597-8264","authenticated-orcid":false,"given":"George","family":"Mochamah","sequence":"additional","affiliation":[{"name":"4Department of Epidemiology and Demography, Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5757-609X","authenticated-orcid":false,"given":"Peter","family":"Olupot-Olupot","sequence":"additional","affiliation":[{"name":"6Mbale Clinical Research Institute, Mbale, Uganda"},{"name":"7Division of Clinical and Infectious Disease Epidemiology, Busitema University, Mbale, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6360-0589","authenticated-orcid":false,"given":"George","family":"Paasi","sequence":"additional","affiliation":[{"name":"6Mbale Clinical Research Institute, Mbale, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4005-9384","authenticated-orcid":false,"given":"Marvin E.","family":"Reid","sequence":"additional","affiliation":[{"name":"8Division of Medical Sciences, Faculty of Medical Sciences, The University of the West Indies, Kingston, Jamaica"},{"name":"9Sickle Cell Unit, Caribbean Institute for Health Research, The University of the West Indies, Kingston, Jamaica"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3535-0911","authenticated-orcid":false,"given":"Angela E.","family":"Rankine-Mullings","sequence":"additional","affiliation":[{"name":"8Division of Medical Sciences, Faculty of Medical Sciences, The University of the West Indies, Kingston, Jamaica"},{"name":"9Sickle Cell Unit, Caribbean Institute for Health Research, The University of the West Indies, Kingston, Jamaica"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3240-2058","authenticated-orcid":false,"given":"Robert O.","family":"Opoka","sequence":"additional","affiliation":[{"name":"10Department of Undergraduate Medical Education, Aga Khan University Medical College, Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1634-1411","authenticated-orcid":false,"given":"Chandy C.","family":"John","sequence":"additional","affiliation":[{"name":"11Division of Pediatric Infectious Diseases and Global Health, Indiana University School of Medicine, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6198-4785","authenticated-orcid":false,"given":"Patrick T.","family":"McGann","sequence":"additional","affiliation":[{"name":"12Brown University Health Comprehensive Sickle Cell Center, Hasbro Children\u2019s Hospital and Rhode Island Hospital, Providence, RI"},{"name":"13Department of Pediatrics, The Warren Alpert Medical School of Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2372-2175","authenticated-orcid":false,"given":"Charles T.","family":"Quinn","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"},{"name":"3Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7655-6094","authenticated-orcid":false,"given":"Nieko C.","family":"Punt","sequence":"additional","affiliation":[{"name":"14Medimatics, Maastricht, The Netherlands"},{"name":"15Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4083-0060","authenticated-orcid":false,"given":"Luke R.","family":"Smart","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"},{"name":"2Department of Pediatrics, Global Health Center, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"},{"name":"3Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0043-5333","authenticated-orcid":false,"given":"Susan E.","family":"Stuber","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"},{"name":"2Department of Pediatrics, Global Health Center, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4473-5821","authenticated-orcid":false,"given":"Teresa S.","family":"Latham","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"},{"name":"2Department of Pediatrics, Global Health Center, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"},{"name":"3Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4224-2967","authenticated-orcid":false,"given":"Alexander A.","family":"Vinks","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9582-0594","authenticated-orcid":false,"given":"Russell E.","family":"Ware","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"},{"name":"2Department of Pediatrics, Global Health Center, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"},{"name":"3Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"issue":"20","key":"2026012709470211500_bib1","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N Engl J Med"},{"issue":"6","key":"2026012709470211500_bib2","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1016\/S2352-3026(24)00145-5","article-title":"Long term strategies for individuals with sickle cell disease","volume":"11","author":"The Lancet Haematology","year":"2024","journal-title":"Lancet Haematol"},{"issue":"13","key":"2026012709470211500_bib3","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMct0708272","article-title":"Hydroxyurea for the treatment of sickle cell anemia","volume":"358","author":"Platt","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"2026012709470211500_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ajh.24235","article-title":"Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: the last 40 years","volume":"91","author":"Chaturvedi","year":"2016","journal-title":"Am J Hematol"},{"issue":"5","key":"2026012709470211500_bib5","first-page":"1061","article-title":"The modern use of hydroxyurea for children with sickle cell anemia","volume":"110","author":"Quinn","year":"2025","journal-title":"Haematologica"},{"issue":"9","key":"2026012709470211500_bib6","doi-asserted-by":"crossref","first-page":"E247","DOI":"10.1002\/ajh.25900","article-title":"Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: final results of the SPIN trial","volume":"95","author":"Galadanci","year":"2020","journal-title":"Am J Hematol"},{"issue":"1","key":"2026012709470211500_bib7","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/S2352-3026(21)00368-9","article-title":"Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial","volume":"9","author":"Abdullahi","year":"2022","journal-title":"Lancet Haematol"},{"issue":"8","key":"2026012709470211500_bib8","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood.2022016620","article-title":"Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial","volume":"141","author":"Abdullahi","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2026012709470211500_bib9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3109\/03630269.2012.697948","article-title":"Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease","volume":"36","author":"Jain","year":"2012","journal-title":"Hemoglobin"},{"issue":"3","key":"2026012709470211500_bib10","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/MOH.0000000000000582","article-title":"Effective use of hydroxyurea for sickle cell anemia in low-resource countries","volume":"27","author":"Power-Hays","year":"2020","journal-title":"Curr Opin Hematol"},{"issue":"26","key":"2026012709470211500_bib11","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1182\/blood-2009-04-146852","article-title":"How I use hydroxyurea to treat young patients with sickle cell anemia","volume":"115","author":"Ware","year":"2010","journal-title":"Blood"},{"issue":"26","key":"2026012709470211500_bib12","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1056\/NEJMoa2000146","article-title":"Hydroxyurea dose escalation for sickle cell anemia in sub-Saharan Africa","volume":"382","author":"John","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"2026012709470211500_bib13","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1016\/S2352-3026(24)00078-4","article-title":"Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1\/2 trial","volume":"11","author":"Aygun","year":"2024","journal-title":"Lancet Haematol"},{"issue":"4","key":"2026012709470211500_bib14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/ajh.27244","article-title":"Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: analysis from the phase I\/II REACH trial","volume":"99","author":"Power-Hays","year":"2024","journal-title":"Am J Hematol"},{"issue":"8","key":"2026012709470211500_bib15","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/bloodadvances.2024014327","article-title":"Stroke prevention in Hispanic children with sickle cell anemia: the SACRED trial","volume":"9","author":"Nieves","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"2026012709470211500_bib16","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/S2352-3026(22)00405-7","article-title":"Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial","volume":"10","author":"Ambrose","year":"2023","journal-title":"Lancet Haematol"},{"issue":"18","key":"2026012709470211500_bib17","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1182\/blood-2011-07-364190","article-title":"Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia","volume":"118","author":"Ware","year":"2011","journal-title":"Blood"},{"key":"2026012709470211500_bib18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bcmd.2017.08.009","article-title":"Hydroxyurea: analytical techniques and quantitative analysis","volume":"67","author":"Marahatta","year":"2017","journal-title":"Blood Cells Mol Dis"},{"key":"2026012709470211500_bib19","doi-asserted-by":"crossref","first-page":"765958","DOI":"10.3389\/fgene.2021.765958","article-title":"Barriers to therapeutic use of hydroxyurea for sickle cell disease in Nigeria: a cross-sectional survey","volume":"12","author":"Okocha","year":"2021","journal-title":"Front Genet"},{"key":"2026012709470211500_bib20","doi-asserted-by":"crossref","first-page":"921432","DOI":"10.3389\/fgene.2022.921432","article-title":"Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: report from a U.S. regional collaborative","volume":"13","author":"Treadwell","year":"2022","journal-title":"Front Genet"},{"issue":"8","key":"2026012709470211500_bib21","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ajh.24770","article-title":"Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial)","volume":"92","author":"Galadanci","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"2026012709470211500_bib22","first-page":"1689","article-title":"A pharmacist-managed hydroxyurea prescribing protocol improves uptake and optimization among patients with sickle cell disease","volume":"5","author":"de Almeida","year":"2016","journal-title":"Adv Hematol"},{"issue":"6","key":"2026012709470211500_bib23","doi-asserted-by":"crossref","first-page":"e28969","DOI":"10.1002\/pbc.28969","article-title":"Hydroxyurea in children with sickle cell disease in a resource-poor setting: monitoring and effects of therapy. A practical perspective","volume":"68","author":"Nnebe-Agumadu","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2026012709470211500_bib24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2165\/00003088-199834050-00002","article-title":"Pharmacokinetics and pharmacodynamics of hydroxyurea","volume":"34","author":"Gwilt","year":"1998","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2026012709470211500_bib25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/cpt.2028","article-title":"Changing the clinical paradigm of hydroxyurea treatment for sickle cell anemia through precision medicine","volume":"109","author":"Dong","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"2026012709470211500_bib26","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/bcp.12851","article-title":"Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia","volume":"81","author":"Dong","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"2026012709470211500_bib27","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/ajh.25510","article-title":"Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia","volume":"94","author":"McGann","year":"2019","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2026012709470211500_bib28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1182\/blood-2024-200426","article-title":"Individualized, PK-guided dosing of hydroxyurea for young children with sickle cell anemia: final results from the hydroxyurea optimization through precision study (HOPS)","volume":"144","author":"Appiah-Kubi","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026012709470211500_bib29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/bjh.17663","article-title":"Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia","volume":"194","author":"Quinn","year":"2021","journal-title":"Br J Haematol"},{"issue":"4","key":"2026012709470211500_bib30","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/0091270004273526","article-title":"The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease","volume":"45","author":"Yan","year":"2005","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"2026012709470211500_bib31","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/jcph.598","article-title":"Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia","volume":"56","author":"Estepp","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"16","key":"2026012709470211500_bib32","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1182\/bloodadvances.2023010099","article-title":"Efficacy, safety, and pharmacokinetics of a new, ready-to-use, liquid hydroxyurea in children with sickle cell anemia","volume":"7","author":"Rankine-Mullings","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"2026012709470211500_bib33","first-page":"1685","article-title":"Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease","volume":"91","author":"de Montalembert","year":"2006","journal-title":"Haematologica"},{"issue":"5","key":"2026012709470211500_bib34","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3390\/pharmaceutics14051065","article-title":"Mathematical modeling of hydroxyurea therapy in individuals with sickle cell disease","volume":"14","author":"Pandey","year":"2022","journal-title":"Pharmaceutics"},{"issue":"6","key":"2026012709470211500_bib35","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3390\/ph16060857","article-title":"Effectiveness of pharmacokinetic-guided hydroxyurea dose individualization in patients with sickle cell anemia: a mini-review","volume":"16","author":"dos Santos Neres","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"9","key":"2026012709470211500_bib36","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/jcph.303","article-title":"Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease","volume":"54","author":"Wiczling","year":"2014","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"2026012709470211500_bib37","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/bjh.17698","article-title":"Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial","volume":"195","author":"Rankine-Mullings","year":"2021","journal-title":"Br J Haematol"},{"issue":"3","key":"2026012709470211500_bib38","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/cpt.3119","article-title":"Rationale, development, and validation of HdxSim, a clinical decision support tool for model-informed precision dosing of hydroxyurea for children with sickle cell anemia","volume":"116","author":"Power-Hays","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"S450","key":"2026012709470211500_bib39","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1651-2227.2006.tb02378.x","article-title":"WHO child growth standards","volume":"95","author":"de Onis","year":"2006","journal-title":"Acta Paediatr"},{"issue":"2","key":"2026012709470211500_bib40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1542\/peds.58.2.259","article-title":"A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine","volume":"58","author":"Schwartz","year":"1976","journal-title":"Pediatrics"},{"issue":"1","key":"2026012709470211500_bib41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00001648-199001000-00010","article-title":"No adjustments are needed for multiple comparisons","volume":"1","author":"Rothman","year":"1990","journal-title":"Epidemiology"},{"issue":"2","key":"2026012709470211500_bib42","first-page":"189","article-title":"Why we (usually) don\u2019t have to worry about multiple comparisons","volume":"5","author":"Gelman","year":"2012","journal-title":"J Res Educ Eff"},{"key":"2026012709470211500_bib43","doi-asserted-by":"crossref","first-page":"111688","DOI":"10.1016\/j.jclinepi.2025.111688","article-title":"To adjust, or not to adjust, for multiple comparisons","volume":"180","author":"Hooper","year":"2025","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"2026012709470211500_bib44","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.athoracsur.2015.11.024","article-title":"Adjust for multiple comparisons? It\u2019s not that simple","volume":"101","author":"Althouse","year":"2016","journal-title":"Ann Thorac Surg"},{"issue":"10","key":"2026012709470211500_bib45","doi-asserted-by":"crossref","first-page":"8792","DOI":"10.3390\/ijms24108792","article-title":"Are genetic modifiers the answer to different responses to hydroxyurea treatment?\u2014A pharmacogenetic study in sickle cell anemia angolan children","volume":"24","author":"Ginete","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"suppl 1","key":"2026012709470211500_bib46","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood-2024-208608","article-title":"Pharmacokinetic (PK)-guided dosing of hydroxyurea for Tanzanian children with sickle cell anemia","volume":"144","author":"Smart","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2026012709470211500_bib47","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.exphem.2011.01.004","article-title":"Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters","volume":"39","author":"Walker","year":"2011","journal-title":"Exp Hematol"},{"issue":"1","key":"2026012709470211500_bib48","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jpeds.2009.06.060","article-title":"Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial","volume":"156","author":"Ware","year":"2010","journal-title":"J Pediatr"},{"issue":"23","key":"2026012709470211500_bib49","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1182\/bloodadvances.2019000883","article-title":"End points for sickle cell disease clinical trials : renal and cardiopulmonary, cure, and low-resource settings","volume":"3","author":"Farrell","year":"2019","journal-title":"Blood Adv"},{"issue":"21","key":"2026012709470211500_bib50","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood.V118.21.2131.2131","article-title":"Predicting hydroxyurea responses in children with sickle cell anemia","volume":"118","author":"Ware","year":"2011","journal-title":"Blood"},{"issue":"suppl 1","key":"2026012709470211500_bib51","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1182\/blood-2024-208408","article-title":"Effects of splenomegaly in children with sickle cell anemia treated with hydroxyurea: secondary analysis of the Sphere trial","volume":"144","author":"Ambrose","year":"2024","journal-title":"Blood"},{"issue":"9778","key":"2026012709470211500_bib52","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"The Lancet"},{"issue":"24","key":"2026012709470211500_bib53","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2017-06-788935","article-title":"Novel use of hydroxyurea in an African region with malaria (NOHARM): a trial for children with sickle cell anemia","volume":"130","author":"Opoka","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2026012709470211500_bib54","first-page":"208","article-title":"Pharmacokinetic-guided hydroxyurea to reduce transfusions in Ugandan children with sickle cell anemia: study design of the Alternative Dosing And Prevention of Transfusions trial","volume":"148","author":"Power-Hays","year":"2025","journal-title":"Acta Haematol"},{"issue":"suppl 1","key":"2026012709470211500_bib55","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1182\/blood-2022-163202","article-title":"Optimizing dose and limiting laboratory monitoring of hydroxyurea in Africa: design of the promoting utilization and safety of hydroxyurea using precision in Africa (PUSH-UP) trial","volume":"140","author":"McGann","year":"2022","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/2\/418\/2498277\/blooda_adv-2025-017254-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/2\/418\/2498277\/blooda_adv-2025-017254-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:47:14Z","timestamp":1769525234000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/2\/418\/547533\/Hydroxyurea-pharmacokinetics-in-children-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017254","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,27]]},"published":{"date-parts":[[2026,1,16]]}}}